MONOKLONAL ANTITANACHALAR: ALZGEYMER KASALLIGINI DAVOLASHDAGI YANGI DAVR

Zenodo (CERN European Organization for Nuclear Research) 2026 Dataset Open access

Read full text
Authors: Mazmunaxon Mamajonova, Xodjayeva Muqaddas Sati- Maxamatovna, Worldly Knowledge Publishing Centre
DOI: 10.5281/zenodo.18599935
Cited by: 0

Abstract

Lekanemab va donanemab kabi miyadagi beta-amiloidni nishonga oluvchi monoklonal antitanachalar (MAT) kasallikning erta bosqichidagi bemorlarda kognitiv pasayishni sekinlashtirib, Alzgeymer kasalligini davolashda patogenetik (kasallikni o‘zgartiruvchi) yangi davrni boshlab berdi. AQSH oziq-ovqat va farmatsevtika idorasi (FDA) tomonidan tasdiqlangan ushbu terapiyalar immunoterapiya orqali amiloid g’umbaklarini tozalaydi va an’anaviy simptomatik dori vositalaridan farqli o‘laroq, yangicha yondashuvni taklif etadi. Biroq, ular miya shishishi yoki qon quyilishi (ARIA) kabi xavflar bilan birga kechadi.

Fields of Study & Subjects

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Amyloidosis: Diagnosis Treatment Outcomes

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
10 February 2026
Document type
Dataset